Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Biochem Biophys Res Commun ; 174(3): 1117-24, 1991 Feb 14.
Artículo en Inglés | MEDLINE | ID: mdl-1996980

RESUMEN

The effects of intracisternal (ic) injection of recombinant interleukin-1 beta (IL-1) on absolute ethanol-induced gastric necrotic lesions were studied in conscious rats. IL-1 given ic inhibited ethanol-induced gastric lesions. The cytoprotective effect was dose dependent (ED175 ng/rat), long lasting with a maximal action when given 1-3 h prior to ethanol, blocked by ic injection of a IL-1 receptor antagonist protein (IRAP), and by intraperitoneal injection of indomethacin. IL-1, injected ic, was detected in the peripheral blood. However, IL-1 serum levels were lower after IL-1 injection ic than after ip at a dose giving equal gastric protection. These data show that ic IL-1 induces long lasting gastric protection mediated by interaction with IL-1 receptors and prostaglandin pathways at central and/or peripheral sites that remain to be localized.


Asunto(s)
Interleucina-1/farmacología , Proteínas Recombinantes/farmacología , Médula Espinal/fisiología , Estómago/patología , Animales , Supervivencia Celular/efectos de los fármacos , Etanol/toxicidad , Femenino , Indometacina/farmacología , Inyecciones , Inyecciones Espinales , Interleucina-1/administración & dosificación , Interleucina-1/sangre , Masculino , Necrosis , Ratas , Ratas Endogámicas , Proteínas Recombinantes/administración & dosificación , Médula Espinal/efectos de los fármacos , Estómago/efectos de los fármacos
2.
Life Sci ; 48(2): 123-34, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1825231

RESUMEN

Human recombinant interleukin 1 beta (IL-1) administered intraperitoneally to rats produced the following gastric effects: 1. It was cytoprotective, preventing gastric mucosal necrosis produced by oral administration of one ml of absolute ethanol to fasted animals. The ED50 was 1200 units/kg (110 ng per animal). IL-1 was 125 times more potent than prostaglandin E2 (on a weight basis), and 6,000 times more potent (on a molar basis). 2. The cytoprotective effect of IL-1 was blocked by indomethacin (inhibitor of prostaglandin synthesis) and by IRAP (a specific interleukin-1 receptor antagonist protein). IRAP did not inhibit cytoprotection induced by PGE2. 3. IL-1 prevented the formation of gastric erosions induced by aspirin. 4. IL-1 inhibited gastric secretion (volume, acid concentration and output), in the pylorus-ligated rat, with an ED50 of 300 units/kg (3.2 ng per animal). 5. Indomethacin and IRAP blocked the antisecretory effect of IL-1. 6. IL-1 retarded gastric emptying, an effect blocked by IRAP, but not by indomethacin. 7. IL-1 increased synthesis of prostaglandin E2 by the gastric mucosa by 111%. IL-1 is the most potent of known agents that are gastric cytoprotective, antiulcer, antisecretory, and delay gastric emptying. It appears to act mostly by stimulating the synthesis of prostaglandins by the stomach. These studies suggest that the stomach possesses IL-1 receptors. These are probably located on parietal cells (that produce acid), on prostaglandin-producing cells, on smooth muscle cells (responsible for gastric emptying), and on as yet unidentified cells involved in gastric cytoprotection. Both IL-1 and IRAP, being natural substances, may play a physiological role in the maintenance of gastric mucosal integrity, and in the regulation of acid secretion and gastric motility.


Asunto(s)
Dinoprostona/biosíntesis , Vaciamiento Gástrico/efectos de los fármacos , Mucosa Gástrica/metabolismo , Interleucina-1/farmacología , Sialoglicoproteínas , Animales , Antiulcerosos/farmacología , Supervivencia Celular/efectos de los fármacos , Quimioterapia Combinada , Femenino , Jugo Gástrico/efectos de los fármacos , Mucosa Gástrica/efectos de los fármacos , Humanos , Indometacina/farmacología , Proteína Antagonista del Receptor de Interleucina 1 , Interleucina-1/antagonistas & inhibidores , Prostaglandinas/fisiología , Proteínas/farmacología , Ratas , Ratas Endogámicas , Proteínas Recombinantes/farmacología , Estómago/efectos de los fármacos , Estómago/fisiología , Factor de Necrosis Tumoral alfa/farmacología
3.
Lab Invest ; 60(5): 677-91, 1989 May.
Artículo en Inglés | MEDLINE | ID: mdl-2469859

RESUMEN

Acute edematous pancreatitis was produced in rats by subcutaneous administration of caerulein. Pancreas weight, pancreas histology and plasma amylase were used as endpoints to quantitate the severity of the syndrome. A caerulein dose of 10 micrograms/kg.hour produced the most severe pancreatitis, whereas at 5 micrograms/kg.hour the values were half-maximal. The pancreatic lesions were characterized by edema, formation of cytoplasmic vacuoles, leukocytic infiltration, necrosis, and with time (12-hour caerulein infusion) dilated acini. Cholecystokinin octapeptide also produced pancreatitis when given at ten times the dose required for caerulein (50 micrograms/kg.hour instead of 5 micrograms/kg.hour). Carbachol did not induce pancreatitis. Two prostaglandins, 16,16-dimethyl prostaglandin E2 injected subcutaneously and prostaglandin E2 infused subcutaneously, dose dependently prevented caerulein-induced pancreatitis (pancreatic edema, leukocytic infiltration, and necrosis) and reduced the number and size of intracellular vacuoles. The ED50 were 15 to 25 micrograms/kg for 16,16-dimethyl prostaglandin E2 and 90 micrograms/kg.hour for prostaglandin E2. Neither prostaglandin, given at doses inhibiting the development of pancreatitis, prevented the retardation of gastric emptying caused by caerulein, a finding suggesting that the prostaglandins may act specifically on the effect of caerulein on the pancreas but not on caerulein receptors in gastric smooth muscle. Indomethacin, an inhibitor of prostaglandin synthesis, and methscopolamine bromide, an anticholinergic agent, had no effect on caerulein-induced pancreatitis. We concluded that prostaglandins of the E type prevent the development of caerulein-induced pancreatitis. The mechanism by which prostaglandins protect the pancreas may involve stabilization of lysosomes within the acinar cells and inhibition of intracellular activation of pancreatic digestive enzymes.


Asunto(s)
16,16-Dimetilprostaglandina E2/uso terapéutico , Dinoprostona/uso terapéutico , Páncreas/patología , Pancreatitis/prevención & control , Prostaglandinas E Sintéticas/uso terapéutico , Amilasas/sangre , Animales , Carbacol/administración & dosificación , Carbacol/toxicidad , Ceruletida/administración & dosificación , Ceruletida/toxicidad , Colecistoquinina/administración & dosificación , Colecistoquinina/toxicidad , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Indometacina/farmacología , Infusiones Parenterales , Tamaño de los Órganos , Páncreas/efectos de los fármacos , Pancreatitis/inducido químicamente , Pancreatitis/patología , Ratas
4.
Gastroenterology ; 95(4): 932-44, 1988 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-3165897

RESUMEN

Antral ulcers account for about half of gastric ulcers in humans. An animal model was developed to produce such ulcers. Indomethacin given subcutaneously to normally fed hamsters produced antral ulcers within 1-5 h, dose dependently. These ulcers penetrated the muscularis mucosae. With repeated administration of indomethacin and longer duration of treatment, the lesions became more severe and most animals died with perforated antral ulcers after 2-5 days. Like indomethacin, aspirin given orally also produced antral ulcers in hamsters. Indomethacin reduced the formation of prostaglandin E2, prostaglandin F2 alpha, and 6-keto prostaglandin F1 alpha by the antral mucosa, and increased gastric acid output more than twofold. The ulcers were prevented by various antisecretory agents (cimetidine, methscopolamine bromide, and omeprazole), and the antiulcer dose of each of these agents corresponded to the antisecretory dose. By contrast, several prostaglandins prevented the ulcers at very low, nonantisecretory doses. 16,16-Dimethyl prostaglandin E2 prevented the ulcers at a dose nearly 3000 times lower than the gastric antisecretory ED50. The mechanism by which prostaglandins prevent formation of these ulcers is unknown, but the effect is consistent with cytoprotection, i.e., protection of the gastric mucosa by nonantisecretory doses. Indomethacin-induced antral ulcers appear to depend on two factors: a depletion of prostaglandin content of the antrum and gastric hyperacidity.


Asunto(s)
Modelos Animales de Enfermedad , Indometacina , Úlcera Gástrica/inducido químicamente , Administración Oral , Animales , Aspirina/farmacología , Cimetidina/farmacología , Cricetinae , Dinoprostona , Ácido Gástrico/metabolismo , Indometacina/administración & dosificación , Inyecciones Subcutáneas , Masculino , Mesocricetus , Omeprazol/uso terapéutico , Úlcera Péptica Perforada/prevención & control , Prostaglandinas E/administración & dosificación , Prostaglandinas E/farmacología , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA